Effects of MAP4K inhibition on neurite outgrowth.
High content screening
Mitogen-activated protein kinase kinase kinase kinases (MAP4Ks)
Neurite growth
Psychiatric disorders
Synaptogenesis
Journal
Molecular brain
ISSN: 1756-6606
Titre abrégé: Mol Brain
Pays: England
ID NLM: 101468876
Informations de publication
Date de publication:
18 Nov 2023
18 Nov 2023
Historique:
received:
05
08
2023
accepted:
01
11
2023
medline:
20
11
2023
pubmed:
19
11
2023
entrez:
19
11
2023
Statut:
epublish
Résumé
Protein kinases are responsible for protein phosphorylation and are involved in important intracellular signal transduction pathways in various cells, including neurons; however, a considerable number of poorly characterized kinases may be involved in neuronal development. Here, we considered mitogen-activated protein kinase kinase kinase kinases (MAP4Ks), related to as candidate regulators of neurite outgrowth and synaptogenesis, by examining the effects of a selective MAP4K inhibitor PF06260933. PF06260933 treatments of the cultured neurons reduced neurite lengths, not the number of synapses, and phosphorylation of GAP43 and JNK, relative to the control. These results suggest that MAP4Ks are physiologically involved in normal neuronal development and that the resultant impaired neurite outgrowth by diminished MAP4Ks' activity, is related to psychiatric disorders.
Identifiants
pubmed: 37980537
doi: 10.1186/s13041-023-01066-2
pii: 10.1186/s13041-023-01066-2
pmc: PMC10656890
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79Subventions
Organisme : Japan Society for the Promotion of Science
ID : #20H03597
Organisme : Japan Society for the Promotion of Science
ID : #21K07496
Organisme : Japan Society for the Promotion of Science
ID : #18H04013
Organisme : Japan Agency for Medical Research and Development
ID : #21gm1210007s0103
Organisme : Japan Agency for Medical Research and Development
ID : #22gm1210007s0104
Organisme : Japan Agency for Medical Research and Development
ID : #23gm1210007s0105
Informations de copyright
© 2023. The Author(s).
Références
Cancers (Basel). 2023 Apr 13;15(8):
pubmed: 37190200
J Neurosci. 2017 Nov 15;37(46):11074-11084
pubmed: 28993483
Cell Rep. 2020 Jul 7;32(1):107860
pubmed: 32640226
Nat Rev Neurosci. 2014 May;15(5):285-99
pubmed: 24739785
Biochim Biophys Acta. 2011 Sep;1813(9):1619-33
pubmed: 21167873
ACS Med Chem Lett. 2015 Oct 06;6(11):1128-33
pubmed: 26617966
Nat Commun. 2015 Dec 21;6:8995
pubmed: 26688060
Mol Psychiatry. 2011 Oct;16(10):1006-23
pubmed: 20838393
Hippocampus. 2010 Jan;20(1):58-64
pubmed: 19437419
iScience. 2018 Jun 29;4:190-203
pubmed: 30240740
Schizophr Bull. 2009 Jan;35(1):96-108
pubmed: 19023125
Neurosci Biobehav Rev. 2021 Dec;131:792-805
pubmed: 34634357
J Cell Biol. 2021 Jul 5;220(7):
pubmed: 34086051
Neuropsychol Rev. 2010 Dec;20(4):327-48
pubmed: 21042938
Nat Rev Genet. 2013 May;14(5):347-59
pubmed: 23568486
Adv Immunol. 2016;129:277-314
pubmed: 26791862
Biochem Pharmacol. 1996 Nov 8;52(9):1399-405
pubmed: 8937450
Hum Genet. 2023 Mar;142(3):343-350
pubmed: 36469137
J Neurosci. 2012 Oct 3;32(40):13987-99
pubmed: 23035106
Mol Psychiatry. 2012 Sep;17(9):887-905
pubmed: 22584867
J Neurosci Methods. 2020 Jun 1;339:108723
pubmed: 32277943
Nat Methods. 2005 Jan;2(1):17-25
pubmed: 15789031
Mol Brain. 2022 Jul 26;15(1):68
pubmed: 35883152
J Biol Chem. 1999 Oct 22;274(43):30729-37
pubmed: 10521462
Nature. 2009 Aug 6;460(7256):753-7
pubmed: 19571809
Science. 1996 Nov 15;274(5290):1123-33
pubmed: 8895455
Int J Mol Sci. 2022 Aug 20;23(16):
pubmed: 36012658
Front Oncol. 2022 Dec 08;12:1059513
pubmed: 36568222